Levi & Korsinsky, LLP announces that an ANVS class action lawsuit has been filed on behalf of investors who purchased Annovis Bio, Inc.  (ANVS) securities between May 21, 2021, and July 28, 2021. For more on the ANVS Lawsuit please contact us today.

According to the Annovis Bio lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Annovis’s ANVS401 (Posiphen), an orally administrated drug that purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

TO LEARN MORE ABOUT THE ANVS CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Annovis Bio you have until October 18, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com